{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:00:55Z","timestamp":1780671655431,"version":"3.54.1"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The use of biological immunotherapeutic drugs is one of the options currently being evaluated and employed to manage COVID-19, specifically monoclonal antibodies, which have shown benefit by regulating the excessive immune response seen in patients with severe infection, known as a cytokine storm. Tocilizumab has received particular importance for this clinical application, as has sarilumab. Both drugs share a substantial similarity in terms of pharmacodynamics, being inhibitors of the interleukin six receptor (IL-6R\u03b1). Furthermore, sotrovimab, a neutralizing anti-SARS CoV-2 antibody, has gained the attention of the scientific community since it has recently been authorized under certain circumstances, positioning itself as a new therapeutic alternative in development. However, despite their clinical benefit, biological immunotherapies have the potential to generate life-threatening immune-related adverse events. Therefore it is essential to review their incidence, mechanism, and risk factors. This review aims to provide a comprehensive understanding of the safety of the biological immunotherapeutic drugs currently recommended for the treatment of COVID-19, provide a review of the known immune-mediated adverse events and explore the potential immune-related mechanisms of other adverse reactions.<\/jats:p>","DOI":"10.3389\/fphar.2022.973246","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T11:43:33Z","timestamp":1661514213000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Immune-related adverse events of biological immunotherapies used in COVID-19"],"prefix":"10.3389","volume":"13","author":[{"given":"Daniela","family":"Baracaldo-Santamar\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Mar\u00eda","family":"Barros-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Hern\u00e1ndez-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"De-La-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos-Alberto","family":"Calderon-Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"B1","unstructured":"Clinical trial safety profile side effects | ACTEMRA\u00ae (tocilizumab)\n            ActemeraS.\n          2022"},{"key":"B2","unstructured":"Actemra\/RoActemra approved by the European commission to [internet]2022"},{"key":"B3","article-title":"Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring adressed to member states for unauthorised product sotrovimab available for use","author":"Annex","year":"2021"},{"key":"B4","unstructured":"Anti-IL6 and corticosteroid monotherapy vs combination in COVID-19 - full text view - ClinicalTrials.gov\n            Anti-Il6 and Corticosteroid Monotherapy\n          2022"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.33706\/jemcr.816161","article-title":"Tocilizumab-induced anaphylaxis in two patients with COVID19induced cytokine storm","volume":"12","author":"Atayik","year":"2021","journal-title":"J. Emerg. Med. Case Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1002\/art.38461","article-title":"A45: Neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with polyarticular-course juvenile idiopathic arthritis","volume":"66","author":"Benedetti","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2022.2136","article-title":"Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials","author":"Boppana","year":"2022","journal-title":"Monaldi Archives Chest Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/asheducation.V2012.1.174.3798251","article-title":"How to approach neutropenia","volume":"2012","author":"Boxer","year":"2012","journal-title":"Hematology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","article-title":"Efficacy and safety of tocilizumab in severe COVID-19 patients: A single-centre retrospective cohort study","volume":"76","author":"Campochiaro","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.18176\/jiaci.0314","article-title":"Successful slow desensitization to tocilizumab in a 15-year-old patient","volume":"28","author":"Cansever","year":"2018","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: A randomized clinical trial","volume":"326","author":"Caricchio","year":"2021","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1016\/S2665-9913(21)00012-6","article-title":"Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: A cohort study","volume":"3","author":"Cavalli","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1080\/14740338.2021.1946513","article-title":"Tocilizumab in COVID-19: A study of adverse drug events reported in the WHO database","volume":"20","author":"Charan","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"E005","DOI":"10.3760\/cma.j.issn.1001-0939.2020.0005","article-title":"Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia","volume":"43","author":"Chen","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B16","unstructured":"Committee for medicinal products for human use (CHMP) CHMP assessment report2021"},{"key":"B17","article-title":"No title","year":"2021"},{"key":"B18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor \u03b1 agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.3389\/fimmu.2021.782506","article-title":"In silico analyses on the comparative potential of therapeutic human monoclonal antibodies against newly emerged SARS-CoV-2 variants bearing mutant spike protein","volume":"12","author":"Das","year":"2022","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2174\/1570180818666210901125519","article-title":"In silico identification of new anti-SARS-CoV-2 agents from bioactive phytocompounds targeting the viral spike glycoprotein and human TLR4","volume":"19","author":"Das","year":"2021","journal-title":"Lett. Drug Des. Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S2213-2600(21)00377-5","article-title":"Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-aid): A factorial, randomised, controlled trial","volume":"9","author":"Declercq","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"del Valle","year":"","journal-title":"Nat. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"del Valle","year":"","journal-title":"Nat. Med."},{"key":"B24","unstructured":"Fact Sheet for Healthcare Providers emergency use authorization (eua) of sotrovimab authorized use2022"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070783","article-title":"Biologics in COVID-19 so far: Systematic review","volume":"15","author":"Eynde","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B26","unstructured":"EMERGENCY USE AUTHORIZATION FOR ACTEMRA \u00ae (tocilizumab) HIGHLIGHTS OF EMERGENCY USE AUTHORIZATION (EUA) These highlights of the EUA do not include all the information needed to use ACTEMRA under the EUA2021"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"B29","doi-asserted-by":"publisher","first-page":"105960","DOI":"10.1016\/j.ijantimicag.2020.105960","article-title":"Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection","volume":"55","author":"Fantini","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B30","unstructured":"FDA updates Sotrovimab emergency use authorization | FDA [Internet]2022"},{"key":"B31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/rheumatology\/kez265","article-title":"Long-term safety of sarilumab in rheumatoid arthritis: An integrated analysis with up to 7 years\u2019 follow-up","volume":"59","author":"Fleischmann","year":"2020","journal-title":"Rheumatology"},{"key":"B32","unstructured":"Highlights of prescribing information\n            Food and Drug Administration"},{"key":"B33","unstructured":"Highlights of prescribing information - sylvant (siltuximab)\n            Food and Drug Administration"},{"key":"B34","unstructured":"Highlights of prescribing information\n            Food and Drug Administration"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"B36","first-page":"75","article-title":"Subcutaneous IL-6 inhibitor sarilumab vs. Standard care in hospitalized patients with moderate-to-severe COVID-19: An open label randomized clinical trial","volume-title":"Front. Med.","author":"Garc\u00eda-Vicu\u00f1a","year":""},{"key":"B37","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/bcp.14459","article-title":"Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19","volume":"87","author":"Gatti","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-020-02194-z[","article-title":"Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies","volume":"22","author":"Genovese","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/art.40176","article-title":"Transaminase levels and hepatic events during tocilizumab treatment: Pooled analysis of long-term clinical trial safety data in rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B40","first-page":"13","article-title":"Itolizumab treatment for cytokine release syndrome in moderate to severe acute respiratory distress syndrome due to COVID-19: Clinical outcomes, A retrospective study - PubMed","volume":"69","author":"Gore","year":"2021","journal-title":"J. Assoc. Physicians India"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e6982","DOI":"10.7759\/cureus.6982","article-title":"Organizing pneumonia induced by tocilizumab in a patient with rheumatoid arthritis","volume":"12","author":"Gouveia","year":"2020","journal-title":"Cureus"},{"key":"B42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.24875\/AIDSRev.200001261","article-title":"The importance of understanding the stages of COVID-19 in treatment and trials","volume":"23","author":"Griffin","year":"2021","journal-title":"AIDS Rev."},{"key":"B43","unstructured":"An observational study of the use of siltuximab (SYLVANT) in patients diagnosed with COVID-19 infection who have developed serious respiratory complications\n            GrittiG.\n            GiovanniO.\n          2022"},{"key":"B44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/jim-2021-002001","article-title":"Tocilizumab in patients hospitalized with COVID-19 pneumonia: Systematic review and meta-analysis of randomized controlled trials","volume":"70","author":"Gupta","year":"","journal-title":"J. Investig. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: A randomized clinical trial","volume":"327","author":"Gupta","year":"","journal-title":"JAMA"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"B47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"the immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102945","article-title":"Comparative study of cytokine storm treatment in patients with COVID-19 pneumonia using immunomodulators","volume":"11","author":"Hecker","year":"2022","journal-title":"J. Clin. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial","volume":"81","author":"Hermine","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"B50","unstructured":"A study to evaluate the efficacy and safety of remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized participants with severe COVID-19 pneumonia"},{"key":"B51","unstructured":"A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia\n            HoffmannRocheLa\n          2022"},{"key":"B52","unstructured":"COVID-19 treatment guidelines [internet]2022"},{"key":"B53","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jaip.2014.04.015","article-title":"Successful rapid tocilizumab desensitization in a patient with Still disease","volume":"2","author":"Justet","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B54","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3904\/kjim.2020.157","article-title":"In vitro activity of lopinavir\/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses","volume":"35","author":"Kang","year":"2020","journal-title":"Korean J. Intern. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","article-title":"Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/iid3.400","article-title":"Efficacy of canakinumab in mild or severe COVID-19 pneumonia","volume":"9","author":"Katia","year":"2021","journal-title":"Immun. Inflamm. Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1007\/s00296-010-1525-z","article-title":"A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab","volume":"32","author":"Kawashiri","year":"2012","journal-title":"Rheumatol. Int."},{"key":"B58","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/psp4.12534","article-title":"Population pharmacodynamic model of neutrophil margination and tolerance to describe effect of sarilumab on absolute neutrophil count in patients with rheumatoid arthritis","volume":"9","author":"Kovalenko","year":"2020","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/hep.510310123","article-title":"Increased toxin-induced liver injury and fibrosis in interleukin-6\u2013deficient mice","volume":"31","author":"Kovalovich","year":"2000","journal-title":"Hepatology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.30158","article-title":"Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year","volume":"63","author":"Kremer","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B61","first-page":"675","article-title":"A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19","volume-title":"Expert Opin. Biol. Ther.","author":"Kumar","year":""},{"key":"B62","doi-asserted-by":"publisher","first-page":"21775","DOI":"10.1038\/s41598-020-78492-y","article-title":"Blockage of interleukin-1\u03b2 with canakinumab in patients with Covid-19","volume":"10","author":"Landi","year":"2020","journal-title":"Sci. Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/jmv.27482","article-title":"Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis","volume":"94","author":"Lin","year":"2022","journal-title":"J. Med. Virology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/nsr\/nwaa037","article-title":"Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury","volume":"7","author":"Liu","year":"2020","journal-title":"Natl. Sci. Rev."},{"key":"B65","first-page":"1025","article-title":"Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications","volume-title":"Expert Opin. Biol. Ther.","author":"Loganathan","year":""},{"key":"B66","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/IJGM.S23920","article-title":"Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: Two case reports","volume":"4","author":"Mahamid","year":"2011","journal-title":"Int. J. Gen. Med."},{"key":"B67","unstructured":"Efficacy and safety of siltuximab vs. Corticosteroids in hospitalized patients with COVID-19 pneumonia - full text view - ClinicalTrials.gov [internet]\n            MartinezJ. P.\n          2022"},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.1080\/14656566.2022.2035360","article-title":"Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)","author":"McCarthy","year":"2022"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1128\/aac.02107-21","article-title":"Early use of sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: The SARICOR randomized clinical trial","volume":"66","author":"Merchante","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B70","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/jmv.27489","article-title":"Combination therapy of tocilizumab and steroid for COVID-19 patients: A meta-analysis","volume":"94","author":"Moosazadeh","year":"2022","journal-title":"J. Med. Virology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/rheumatology\/kew370","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: Pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejim.2020.05.011","article-title":"Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy","volume":"76","author":"Morena","year":"2020","journal-title":"Eur. J. Intern Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3899\/jrheum.080930","article-title":"Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis","volume":"36","author":"Nakamura","year":"2009","journal-title":"J. Rheumatol."},{"key":"B74","unstructured":"COVID-19 treatment guidelines 22022"},{"key":"B75","unstructured":"COVID-19 treatment guidelines 22022"},{"key":"B76","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/acr.22110","article-title":"Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis","volume":"66","author":"Ogata","year":"2014","journal-title":"Arthritis Care Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000362266","article-title":"Tocilizumab-induced psoriasiform rash in rheumatoid arthritis","volume":"228","author":"Palmou-Fontana","year":"2014","journal-title":"Dermatology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00296-019-04456-910.1007\/s00296-019-04456-9","article-title":"Tocilizumab-induced anaphylaxis in patients with adult-onset still\u2019s disease and systemic juvenile idiopathic arthritis: A case-based review","volume":"40","author":"Park","year":"2019","journal-title":"Rheumatol. Int."},{"key":"B79","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(22)00282-3","article-title":"Waning of COVID-19 vaccine effectiveness: Individual and public health risk","volume":"399","author":"Piechotta","year":"2022","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19 \u2014","volume":"384","year":"2021","journal-title":"New england journal of medicine"},{"key":"B81","doi-asserted-by":"publisher","first-page":"30408","DOI":"10.18632\/oncotarget.4655","article-title":"A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease","volume":"6","author":"Rhee","year":"2015","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/rheumatology\/keu181","article-title":"Hypersensitivity reactions to tocilizumab: Role of skin tests in diagnosis","volume":"53","author":"Rocchi","year":"2014","journal-title":"Rheumatology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"102506","DOI":"10.1016\/j.jaut.2020.102506","article-title":"Autoinflammatory and autoimmune conditions at the crossroad of COVID-19","volume":"114","author":"Rodr\u00edguez","year":"2020","journal-title":"J. Autoimmun."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"B85","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/phar.2627","article-title":"Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis","volume":"41","author":"Rubio-Rivas","year":"2021","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/rheumatology\/keu008","article-title":"Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis","volume":"53","author":"Sakaue","year":"2014","journal-title":"Rheumatology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with covid-19 pneumonia","volume":"384","author":"Salama","year":"2020","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"B88","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.reumae.2015.08.005","article-title":"Acute pneumonitis in a patient with adult-onset disease after toclizumab treatment with good response to anakinra","volume":"12","author":"Sang\u00fcesa G\u00f3mez","year":"2016","journal-title":"Reumatol. Cl\u00ednica"},{"key":"B89","doi-asserted-by":"publisher","first-page":"8317","DOI":"10.3389\/fimmu.2022.831763","article-title":"The S1 subunit of the SARS-CoV-2 spike protein activates human monocytes to produce cytokines linked to COVID-19: Relevance to galectin-3","volume":"13","author":"Schroeder","year":"2022","journal-title":"Front. Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874306401206010063","article-title":"Drug induced interstitial lung disease","volume":"6","author":"Schwaiblmair","year":"2012","journal-title":"Open Respir. Med. J."},{"key":"B91","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12026-014-8590-4","article-title":"Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: Case series and review of literature","volume":"61","author":"Shovman","year":"2014","journal-title":"Immunol. Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jbspin.2016.04.013","article-title":"Immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"84","author":"Sigaux","year":"2017","journal-title":"Jt. Bone Spine"},{"key":"B93","doi-asserted-by":"publisher","first-page":"s57","DOI":"10.7861\/clinmed.20-2-s57","article-title":"Tocilizumab-induced pulmonary fibrosis in a patient with rheumatoid arthritis","volume":"20","author":"Silva","year":"2020","journal-title":"Clin. Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/PROM.S140011","article-title":"Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease.","volume":"9","author":"Sitenga","year":"2018","journal-title":"Patient Relat. Outcome Meas."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac153\/6537638","article-title":"Efficacy and safety of sarilumab in hospitalized patients with COVID-19: A randomized clinical trial","author":"Sivapalasingam","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"B97","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","article-title":"Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): An open-label, multicentre, randomised, controlled, phase 3 trial","volume":"9","author":"Soin","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B98","unstructured":"Health Canada services drugs-health-products covid19-industry drugsvaccines\n            Sotrovimab Product Monograph\n          2022"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/nejmoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"B100","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13223-021-00594-7","article-title":"Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: A case report","volume":"17","author":"Sugihara","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"H2954","DOI":"10.1152\/ajpheart.2000.279.6.H2954","article-title":"Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow","volume":"279","author":"Suwa","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/mr\/roab066\/6368305","article-title":"Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: Analysis of two phase 3 randomised clinical trials","volume":"32","author":"Tanaka","year":"2021","journal-title":"Mod. Rheumatol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with covid-19","volume":"383","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/nejmoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with covid-19","volume":"384","author":"Theinvestigators","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/S2352-3026(19)30257-1","article-title":"Long-term safety of siltuximab in patients with idiopathic multicentric castleman disease: A prespecified, open-label, extension analysis of two trials","volume":"7","author":"van Rhee","year":"2020","journal-title":"Lancet Haematol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40744-019-0157-3","article-title":"Immunogenicity of sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs","volume":"6","author":"Wells","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"B107","unstructured":"WHO coronavirus (COVID-19) dashboard | WHO coronavirus (COVID-19) dashboard with vaccination data [internet]2022"},{"key":"B108","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jbspin.2014.04.004","article-title":"Tocilizumab-associated cutaneous reactive endotheliomatosis in a patient with rheumatoid arthritis","volume":"82","author":"Wu","year":"2015","journal-title":"Jt. Bone Spine"},{"key":"B109","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.bbrc.2007.07.052","article-title":"The role of IL-6 in inhibition of lymphocyte apoptosis by mesenchymal stem cells","volume":"361","author":"Xu","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B110","unstructured":"Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis\n            YasuokaR.\n            IwataN.\n            AbeN.\n            KohaguraT.\n            NakasekoH.\n            ShimizuM.\n          2019"},{"key":"B111","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1468-3083.2009.03437.x","article-title":"Drug eruption induced by IL-6 receptor inhibitor tocilizumab","volume":"24","author":"Yoshiki","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58020144","article-title":"Cytokine storm in COVID-19: Immunopathogenesis and therapy","volume":"58","author":"Zanza","year":"2022","journal-title":"Medicina"},{"key":"B113","doi-asserted-by":"publisher","first-page":"e28967","DOI":"10.1097\/MD.0000000000028967","article-title":"Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: A systematic review and meta-analysis","volume":"101","author":"Zhang","year":"2022","journal-title":"Medicine"},{"key":"B114","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijid.2020.04.041","article-title":"Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019","volume":"95","author":"Zhu","year":"2020","journal-title":"Int. J. Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.973246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T11:43:46Z","timestamp":1661514226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.973246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":114,"alternative-id":["10.3389\/fphar.2022.973246"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.973246","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"article-number":"973246"}}